ALNY
Alnylam Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$37.76B
P/E Ratio
70.89
EPS
$3.99
Beta
0.27
52W High
$495.55
52W Low
$281.76
50-Day MA
$303.86
200-Day MA
$377.74
Dividend Yield
—
Profit Margin
12.60%
Forward P/E
30.30
PEG Ratio
0.48
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $4.29B |
| Gross Profit (TTM) | $3.46B |
| EBITDA | $806.94M |
| Operating Margin | 23.00% |
| Return on Equity | 90.40% |
| Return on Assets | 10.10% |
| Revenue/Share (TTM) | $32.52 |
| Book Value | $8.06 |
| Price-to-Book | 35.12 |
| Price-to-Sales (TTM) | 8.81 |
| EV/Revenue | 8.4 |
| EV/EBITDA | 41.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 96.40% |
| Shares Outstanding | $133.51M |
| Float | $132.94M |
| % Insiders | 0.18% |
| % Institutions | 102.09% |
Historical Volatility
HV 10-Day
39.98%
HV 20-Day
34.20%
HV 30-Day
33.92%
HV 60-Day
37.12%
HV Rank
33.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($438.52 target)
7
Strong Buy15
Buy8
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026